What medication regimen should be initiated for a patient with total cholesterol 300 mg/dL, triglycerides 200 mg/dL, and LDL cholesterol 210 mg/dL?

Initiate High-Intensity Statin Therapy Immediately

With an LDL cholesterol of 210 mg/dL, total cholesterol of 300 mg/dL, and triglycerides of 200 mg/dL, you should start high-intensity statin therapy immediately to achieve an LDL-C goal of <100 mg/dL, with an optimal target of <70 mg/dL if the patient has atherosclerotic cardiovascular disease or is at very high risk. 1

Primary Treatment Approach

Statin Therapy - First Line

The cornerstone of treatment is statin therapy, which should be initiated regardless of baseline LDL-C levels 1, 2, 3. The guidelines are unequivocal:

• Start with high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) to achieve at least a 30% reduction in LDL-C 1
• The primary goal is LDL-C <100 mg/dL 1, 4
• For very high-risk patients (those with established ASCVD), an LDL-C <70 mg/dL is reasonable 1, 2, 5

Addressing the Elevated Triglycerides

With triglycerides at 200 mg/dL, you have a secondary target: non-HDL cholesterol <130 mg/dL 1. Non-HDL-C is calculated as total cholesterol minus HDL-C, which captures all atherogenic lipoproteins.

The treatment algorithm for triglycerides 200-499 mg/dL:

1. First, optimize statin therapy - statins will lower both LDL-C and triglycerides 1
2. Emphasize lifestyle modifications: weight management, increased physical activity, reduced saturated fat intake (<7% of calories), cholesterol intake <200 mg/day, and elimination of trans fats 1
3. After LDL-C is controlled, if triglycerides remain 200-499 mg/dL and non-HDL-C remains elevated, consider adding:
   • Niacin (prescription form, not dietary supplement) 1, 5
   • OR fibrate therapy (fenofibrate preferred over gemfibrozil when combined with statins to reduce myopathy risk) 1, 5
   • Omega-3 fatty acids (2-4 g/day for triglyceride lowering) may be reasonable 1, 5

Critical Distinction Based on Risk Status

The aggressiveness of your approach depends on whether this patient has:

Very High Risk (established ASCVD, diabetes with target organ damage, or multiple risk factors):

• LDL-C goal: <70 mg/dL 1, 2, 4
• Non-HDL-C goal: <100 mg/dL 1, 5
• Start high-intensity statin immediately
• Consider combination therapy earlier if goals not met

High Risk (without established ASCVD but with risk factors):

• LDL-C goal: <100 mg/dL 1, 4
• Non-HDL-C goal: <130 mg/dL 1
• Start at least moderate-intensity statin, preferably high-intensity given the LDL-C of 210 mg/dL

Practical Implementation

Initial prescription:

• Atorvastatin 40-80 mg daily OR rosuvastatin 20-40 mg daily
• Dietary counseling: <7% saturated fat, <200 mg cholesterol/day, <1% trans fat 1
• Physical activity: 30-60 minutes moderate-intensity aerobic activity at least 5 days/week 1

Follow-up at 4-12 weeks:

• Recheck fasting lipid panel
• Assess for statin adverse effects (muscle symptoms, liver enzymes if clinically indicated)
• If LDL-C remains ≥100 mg/dL despite high-intensity statin, intensify therapy

Intensification options if statin alone insufficient:

• Add ezetimibe 10 mg daily (reduces LDL-C additional 15-20%) 1
• Add bile acid sequestrant 1, 5
• Add PCSK9 inhibitor if very high risk and not at goal despite maximally tolerated statin plus ezetimibe 3, 4

Common Pitfalls to Avoid

• Don't delay statin initiation waiting for lifestyle changes alone - with LDL-C this elevated, pharmacotherapy is indicated immediately 1, 3
• Don't start fibrate before statin unless triglycerides are ≥500 mg/dL (pancreatitis risk) 1
• Don't use gemfibrozil with statins - fenofibrate is safer for combination therapy due to lower myopathy risk 1
• Don't use dietary supplement niacin - only prescription niacin is appropriate 5
• Don't forget to assess for secondary causes of dyslipidemia: hypothyroidism, diabetes, nephrotic syndrome, medications (thiazides, beta-blockers, oral estrogens) 3

Monitoring Strategy

• Lipid panel at 4-12 weeks after initiation or dose change
• Once at goal, recheck every 3-12 months 3
• Monitor for statin-associated muscle symptoms at each visit
• Check liver enzymes only if clinically indicated (symptoms or baseline abnormalities) - routine monitoring not recommended 3

The 2013 ACC/AHA guideline 3 shifted focus from specific LDL-C targets to statin intensity, but the 2011 AHA/ACCF secondary prevention guideline 1 and European guidelines 4 maintain specific LDL-C targets, which remain clinically useful for guiding therapy intensification and are incorporated into the most recent 2026 guidance 6.